

INVITATION

TUESDAY
17
MAY 2022
13:00 – 14:00
CET

ITS 2022 ECP AFTER SOT, THE PROPOSED MOA AND POSSIBLE ROLE IN ABMR AND HIGH RISK PATIENTS

Ballroom 1 – Hotel Titanic, Berlin, Germany

This information is not intended for healthcare professionals based in the US and Canada.

- 13:00 – 13:05 **Introduction**
Dr James Hutchinson, University Hospital Regensburg, Germany
- 13:05 – 13:25 **Immunological mechanism in SOT**
Dr James Hutchinson, University Hospital Regensburg, Germany
- 13:25 – 13:45 **ECP as induction therapy in high risk patients after HTX**
Dr Johannes Gökler, Medical University Vienna, Austria
- 13:45 – 14:00 **Q&A**
James Hutchinson and Johannes Gökler

*ABMR: Antibody-mediated Rejection, ECP: Extracorporeal Photopheresis, HTX: Heart Transplant,
MOA: Mechanism of Action, SOT: Solid Organ Transplant*

All speakers are subject to contract.

***This is a commercial programme run by Therakos (UK) Ltd,
a Mallinckrodt Company.***

[Privacy policy](#)

Follow the
Therakos Institute



For more information on THERAKOS ECP Immunomodulation™ please visit www.therakos.eu
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt
company. Other brands are trademarks of a Mallinckrodt company or their respective owners.
© 2022 Mallinckrodt. Item code: EU-2200087. Date of preparation: April 2022.

*Although we have determined that we have a legitimate interest in using your data for marketing
and sales purposes as per the terms of the current data protection legislation, you can opt-out
by replying to this mail indicating “unsubscribe” in the email body. Our Privacy Notice provides
additional information.*